semaglutide kidney disease in patients with overweight or obesity and chronic without diabetes: a randomized double-blind placebo-controlled clinical trial Kidney and Survival Benefits of

Low IGF-1 levels indicate GH deficiency or receptor insensitivity

An older GLP-1 with somewhat lower efficacy but potentially lower cost, especially as generic options approach

However, experts such as Lydia Alexander, MD, president of the Obesity Medicine Association (OMA) and Chief Medical Officer at Enara, argue that the risks of compounded peptide medications make them a dangerous alternative to approved GLP-1 drugs as they are often produced and sold illegally by unlicensed pharmacies and "bootleggers" taking advantage of drug shortages, potentially containing unknown or dangerous ingredients that could be ineffective or actively harmful to patients

This eliminates travel time and allows you to receive therapy in your most comfortable environment

J.BenceK